35 search results for: coexisting diseases

Neuroimmune Axis in Atopic Dermatitis
expert video

Neuroimmune Axis in Atopic Dermatitis

Dermatology
A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
Neuroimmune Axis and Neuroinflammation in PN
expert video

Neuroimmune Axis and Neuroinflammation in PN

Dermatology
A review of the neuroimmune mechanisms and changes to the dermis that result in itch in PN.
View more
Atopic Dermatitis in Children: Not Just a Skin Disease
expert video

Atopic Dermatitis in Children: Not Just a Skin Disease

Dermatology
In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the multidimensional and cumulative disease burden of AD and its associated comorbidities in children. Dr Boguniewicz also highlights the burden experienced by caregivers of children with AD
View more
The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health
expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

Dermatology
Dr. Marlies de Graaf highlights the potential long-term consequences of AD in children.
View more
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Podcast

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Dermatology
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.
View more
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
expert video

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

Dermatology
This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
View more
The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD
expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

Dermatology
Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.
View more
Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma
Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Pulmonology
Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients
View more
Emerging Perspectives on the Disease Burden and Management of Children With Atopic Dermatitis
expert video

Emerging Perspectives on the Disease Burden and Management of Children With Atopic Dermatitis

Dermatology
This video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria features Drs Christine Bangert, Mark Boguniewicz, and Perla Lansang as they discuss the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, the multidimensional and cumulative disease burden associated with AD and its comorbidities, and the current and emerging treatment options for children with AD uncontrolled with topical therapy
View more
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
expert video

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

Pulmonology
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AustraliaChange country/region